Vanda Pharmaceuticals (VNDA) Non-Current Deferred Tax Liability (2014 - 2017)

Vanda Pharmaceuticals (VNDA) has 4 years of Non-Current Deferred Tax Liability data on file, last reported at -$386000.0 in Q4 2017.

• For the quarter ending Q4 2017, Non-Current Deferred Tax Liability fell 157.96% year-over-year to -$386000.0; the trailing twelve-month figure through Dec 2017 stood at -$386000.0 (down 157.96% YoY), and the FY2017 full-year result was -$386000.0, down 157.96% from the prior year.
• Non-Current Deferred Tax Liability eased to -$386000.0 in Q4 2017, from $666000.0 in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.1 million in Q4 2015 to a low of -$386000.0 in Q4 2017.
• A 4-year average of $346500.0 and a median of $336000.0 in 2014 frame the typical range for Non-Current Deferred Tax Liability.
• Across the five-year window, Non-Current Deferred Tax Liability surged 18233.33% in 2015 and plunged 157.96% in 2017, its largest moves.
• Tracing VNDA's Non-Current Deferred Tax Liability over 4 years: stood at $6000.0 in 2014, then surged by 18233.33% to $1.1 million in 2015, then sank by 39.45% to $666000.0 in 2016, then plunged by 157.96% to -$386000.0 in 2017.
• Business Quant data shows VNDA's Non-Current Deferred Tax Liability at -$386000.0 in Q4 2017, $666000.0 in Q4 2016, and $1.1 million in Q4 2015.